Intravitreal triamcinolone, with a potential clinical activity span of up to three months, can mitigate the infiltration of inflammatory vessels and modulate VEGF expression, consequently reducing macular edema and augmenting visual acuity [30]. The gene discussed is VEGFA; the disease is macular retinal edema.